701 West Main St
5 articles about Tavros Therapeutics
Tavros Therapeutics, Inc. and OpenBench, Inc. today announced the companies have entered into a collaboration agreement to discover small molecule modulators of up to five oncology targets across an initial 18-month term.
Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs
Tavros Therapeutics, Inc. and Vividion Therapeutics, Inc. today announced the companies have entered into a collaboration agreement to discover or target four oncology targets across an initial five-year term.
Vividion Therapeutics and Tavros Therapeutics entered into a five-year collaboration agreement, valued at up to $930 million, to discover and develop four novel oncology targets.
Tavros Therapeutics today announced the completion of a $7.5 million oversubscribed Seed II financing.
Tavros Therapeutics, and OpenBench, today announced a collaboration in which OpenBench will identify novel, potent antagonists against an undisclosed cancer target that was identified by Tavros's proprietary functional genomics platform.